Novartis Study Shows Omalizumab Effective In Severe Form Of Chronic Skin ... NASDAQ (RTTNews.com) - Novartis AG ( NVS ) Saturday announced new results from the Phase III ASTERIA I study showing omalizumab was effective and safe in the treatment of chronic spontaneous urticaria or CSU, a chronic and debilitating form of hives. Novartis says drug reduces itch of severe chronic hives Novartis announces positive results from final Phase III omalizumab registration ... |
View the Original article
